I didn't know either until someone on this forum pointed it out. If you do a google search of `"high dose" site:frequencytx.com`, only 1 result comes back, and it doesn't give any useful information. I've read the same thing that d'Wooluf posted, but I can't find any outside documentation to back it up. I've also read that they went with the high dose for Phase 2a, but that's another thing I can't find any outside documentation on. I would be weary about believing anything without an outside source, as sometimes this forum can act like an echo chamber. Looking back through the thread, at one point people were saying the dose in Phase 2a would be higher than Phase I/II [1], but I can't find anything to back that up either.
I speculate that at least 3 of the 4 responders had a high dose. And now that
@Piney has mentioned that he was rejected for too low of a word score, I wonder if improving high frequency hearing loss has its limits with helping word scores. Maybe those with really low word scores didn't see statistical improvements in Phase I/II even if they had a high dose.
@Piney did they tell you what your word score out of 50 was?
Carl LeBel specifically mentioned trying to recruit people like the "4 responders" for Phase IIa. I think they want really good results for Phase 2a, so they're trying to replicate what happened in those 4 people across a study of 96 people.
That's a good point. I'd just assumed they were the same 4 that had word score improvements, but they never state that anywhere. One thing Carl said in the Goldman Sochs conference that was interesting was that there was a "ceiling" effect to improvement [2, timestamp: 11:34]. I wonder if people from the "mild" hearing loss group couldn't achieve statistical improvements in word score because their scores were already too high. Maybe it was people from this group that saw improvements at 8 kHz.
[1]
https://www.tinnitustalk.com/threads/frequency-therapeutics-—-hearing-loss-regeneration.18889/page-198#post-489070
[2]
https://kvgo.com/GSHC/frequency-therapeutics-june-2020